Indirect Treatment Comparison

Indirect Treatment Comparison

  • Indirect treatment comparison of bevacizumab + interferon-a-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.
    Mickisch GHJ, Schwander B, Escudier B, Bellmunt J, Maroto JP, Porta C, Walzer S, Siebert U
    Clinico Economics and  Outcomes Research 2011: 3; 19-27

Online
PDF

 

 

Indirect Treatment Comparison - GENERAL

  • A Matching-Adjusted Comparative effectiveness analysis of Erlotinib Versus Pemetrexed as First-Line Maintenance Therapies for the Treatment of Advanced or metastatic Non-Small Cell Lung Cancer
    BischoffH, Casciano R,Ray J, Sherman S, Nuijten M, Walzer S; LungCancer 2011: submitted

Online
PDF

 

 

Indirect Treatment Comparison - GENERAL

  • First-line Bevacizumab-based Therapy versus Pemetrexed plus Cisplatin for the Treatment of Advanced Adenocarcinoma Non-Squamous Non-Small Cell Lung Cancer: Comparative Effectiveness Applying Real-Life Outcomes
    Chouaid C, Casciano R, Vergnenegre A,Sherman S, Walzer S; LungCancer 2011: submitted

Online
PDF

 

 

Indirect Treatment Comparison - SUBGROUP

  • An indirect comparison of bevacizumab plus cisplatin/gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced 1st line non-squamous non-small cell lungcancer in East Asia
    Chang JW-C, Wright E, Thongprasert S, Tsang K, Kim HT, Ahn M-J, Kim J-H, Kang HJ, Kim S-W, Walzer S; Asia-Pacific Journal of Clinical Oncology 2011; 7 (suppl 2):13-21

Online
PDF